Potassium Chloride 400 meq/1000mL Injection, Solution — NDC 0990-7077-26 (Billing 00990-7077-26)
This is a package of Potassium Chloride 400 meq/1000mL Injection, Solution from ICU Medical Inc., marketed since Apr 2019 and currently FDA-listed. It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 0990-7077-26 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 0990 labeler · 7077 product · 26 package
- Package marketed since
- Dec 31, 2019
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 0990707726 0
- Medicaid fills, this package
- 133 prescriptions in the last four reported quarters
- FDA record last changed
- Jul 24, 2026
Other active recalls for Potassium Chloride (different manufacturers) — 6 · tap to view
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 015365
- GCN: 03284
- HICL (First Databank): 044754
- AHFS class code: 40:12.00.00
- RxCUI (RxNorm): 312507
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
RxNorm drug class
This medicine belongs to the Potassium class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
- It treats and prevents low potassium. Doctors often use it when you take diuretics or lose fluids through diarrhea or vomiting and food alone isn't enough. The injection is used in...
- Take tablets and capsules with meals, not on an empty stomach, to protect your stomach. Powders and liquids need to be diluted first. Follow your prescriber's directions and keep y...
- The most common issue is stomach upset. Taking it with food helps. Call your doctor if you have severe vomiting, belly pain, swelling or bleeding, since that can mean an ulcer or b...
- Check with me first. Blood pressure medicines such as ACE inhibitors and ARBs, spironolactone, and NSAIDs can raise potassium. Triamterene and amiloride should be avoided with it.
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Potassium Chloride (prescription drug) — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | $0.0105 | $25.20 / 2400 ml |
| Medicare drug plans payPart D · Q2 2026 | $0.0438 | $105.12 / 2400 ml |
| Medicare Part B allowsASP · J3480 | $0.136 / J3480 unit | — |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Billing & reimbursement
Where does this data come from?
- CMS ASP NDC-HCPCS crosswalk · refreshed Sep 22, 2026
- DMEPDAC NDC-HCPCS crosswalk
- openFDA NSDE billing units · refreshed Oct 7, 2026
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 00990-7077-14 0990-7077-14 | 24 POUCH in 1 CASE / 1 BAG in 1 POUCH / 50 mL in 1 BAG | 2019-06-01 | — | Active |
| 00990-7077-26 You're viewing this Main listing | 24 POUCH in 1 CASE / 1 BAG in 1 POUCH / 100 mL in 1 BAG | 2019-12-31 | — | Active |
In Medicaid, this is the most-dispensed pack of this product — about 85% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in this package?
What NDC number is used to bill for this package of Potassium Chloride 400 meq/1000mL Injection, Solution?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Potassium Chloride 400 meq/1000mLthis 00990-7077-26 | ICU | 24 pouches | — | AP | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Potassium Chloride inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
1 inactive ingredient listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 6, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from ICU Medical Inc. labeler code 00990
- Aminosyn-PF ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, and TYROSINE 534 mg/100mL; 831 mg/100mL; 475 mg/100mL; 125 mg/100mL; 300 mg/100mL; 360 mg/100mL; 125 mg/100mL; 452 mg/100mL; 490 mg/100mL; 861 mg/100mL Injection, Solution NDC 0990-4178-03
- Aminosyn-PF ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, and TYROSINE 760 mg/100mL; 1200 mg/100mL; 677 mg/100mL; 180 mg/100mL; 427 mg/100mL; 512 mg/100mL; 180 mg/100mL; 673 mg/100mL; 698 mg/100mL; 1227 mg/100mL Injection, Solution NDC 0990-4179-05
- Potassium Chloride 10 meq/100mL Injection, Solution NDC 0990-7074-26
- Potassium Chloride 200 meq/1000mL Injection, Solution NDC 0990-7075-14
- Potassium Chloride in Dextrose and Sodium 50 g/1000mL; 9 g/1000mL; 1.49 g/1000mL Injection, Solution NDC 0990-7107-09
- Potassium Chloride in Dextrose and Sodium 50 g/1000mL; 9 g/1000mL; 2.98 g/1000mL Injection, Solution NDC 0990-7109-09
- Potassium Chloride in Lactated Ringers and Dextrose POTASSIUM CHLORIDE, SODIUM CHLORIDE, CALCIUM CHLORIDE, SODIUM LACTATE, and DEXTROSE MONOHYDRATE 1.79 g/1000mL; 6 g/1000mL; .2 g/1000mL; 3.1 g/1000mL; 50 g/1000mL Injection, Solution NDC 0990-7111-09
- Potassium Chloride in Sodium 9 g/1000mL; 1.49 g/1000mL Injection, Solution NDC 0990-7115-09
- Potassium Chloride in Sodium 9 g/1000mL; 2.98 g/1000mL Injection, Solution NDC 0990-7116-09
- Sterile Water 1 mL/mL Injection, Solution NDC 0990-7118-07
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🚨 Boxed Warning ▾
Highly Concentrated
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Potassium Chloride Injection is indicated in the treatment of potassium deficiency states when oral replacement is not feasible. THIS HIGHLY CONCENTRATED, READY-TO-USE POTASSIUM CHLORIDE INJECTION IS INTENDED FOR THE MAINTENANCE OF SERUM K + LEVELS AND FOR POTASSIUM SUPPLEMENTATION IN FLUID RESTRICTED PATIENTS WHO CANNOT ACCOMMODATE ADDITIONAL VOLUMES OF FLUID ASSOCIATED WITH POTASSIUM SOLUTIONS OF LOWER CONCENTRATION. When using these products, these patients should be on continuous cardiac monitoring and frequent testing for serum potassium concentration and acid-base balance.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION The dose and rate of administration are dependent upon the specific condition of each patient. Administer intravenously only with a calibrated infusion device at a slow, controlled rate. Because pain associated with peripheral infusion of Potassium Chloride solution has been reported, whenever possible, administration via central route is recommended for thorough dilution by the blood stream and avoidance of extravasation.
Highest concentrations (300 and 400 mEq/L) should be exclusively administered via central route. Recommended administration rates should not usually exceed 10 mEq/hour or 200 mEq for a 24-hour period if the serum potassium level is greater than 2.5 mEq/liter. In urgent cases where the serum potassium level is less than 2 mEq/liter or where severe hypokalemia is a threat (serum potassium level less than 2 mEq/liter and electrocardiographic changes and/or muscle paralysis), rates up to 40 mEq/hour or 400 mEq over a 24-hour period can be administered very carefully when guided by continuous monitoring of the EKG and frequent serum K + determinations to avoid hyperkalemia and cardiac arrest.
Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions where possible. Do not add supplementary medication.
Preparation for Administration (Use aseptic technique) Close flow control clamp of administration set. Remove cover from outlet port at bottom of container. Insert piercing pin of administration set into port with a twisting motion until the set is firmly seated.
NOTE: See full directions on administration set carton. Suspend container from hanger. Squeeze and release drip chamber to establish proper fluid level in chamber.
Open flow control clamp and clear air from set. Close clamp. Attach set to venipuncture device.
If device is not indwelling, prime and make venipuncture. Regulate rate of administration with flow control clamp. WARNING: Do not use flexible container in series connections.
Do not add supplementary medication. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.
⛔ Contraindications ▾
CONTRAINDICATIONS Potassium Chloride Injection is contraindicated in diseases where high potassium levels may be encountered, and in patients with hyperkalemia, renal failure and in conditions in which potassium retention is present.
⚠️ Warnings ▾
WARNINGS THIS HIGHLY CONCENTRATED, READY-TO-USE POTASSIUM CHLORIDE INJECTION IS INTENDED FOR THE MAINTENANCE OF SERUM K + LEVELS AND FOR POTASSIUM SUPPLEMENTATION IN FLUID RESTRICTED PATIENTS WHO CANNOT ACCOMMODATE ADDITIONAL VOLUMES OF FLUID ASSOCIATED WITH POTASSIUM SOLUTIONS OF LOWER CONCENTRATION. TO AVOID POTASSIUM INTOXICATION, DO NOT INFUSE THESE SOLUTIONS RAPIDLY. PATIENTS REQUIRING HIGHLY CONCENTRATED SOLUTIONS SHOULD BE KEPT ON CONTINUOUS CARDIAC MONITORING AND UNDERGO FREQUENT TESTING FOR SERUM POTASSIUM AND ACID-BASE BALANCE, ESPECIALLY IF THEY RECEIVE DIGITALIS.
In patients with renal insufficiency, administration of potassium chloride may cause potassium intoxication and life-threatening hyperkalemia. Administer intravenously only with a calibrated infusion device at a slow, controlled rate. ( See DOSAGE AND ADMINISTRATION .) Because pain associated with peripheral infusion of Potassium Chloride solution has been reported, whenever possible administration via a central route is recommended for thorough dilution by the blood stream and avoidance of extravasation.
Highest concentrations (300 and 400 mEq/L) should be exclusively administered via central route. The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration.
The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Potassium intoxication with mild or severe hyperkalemia has been reported. The signs and symptoms of intoxication include paresthesia of the extremities, areflexia, muscular or respiratory paralysis, mental confusion, weakness, hypotension, cardiac arrhythmia, heart block, electrographic abnormalities and cardiac arrest. EKG abnormalities serve as a clinical reflection of the seriousness of changes in serum potassium concentrations: peaked T waves and prolonged P-R intervals usually occur with modest elevations above the upper limit of normal potassium concentrations; P waves disappear, the QRS complex widens, and eventual asystole usually occurs with higher elevations.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. Infusion of highly concentrated potassium chloride solutions may cause local pain and vein irritation. (See WARNINGS ).
Reactions reported with the use of potassium-containing solutions include nausea, vomiting, and abdominal pain and diarrhea. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
🤰 Pregnancy ▾
Pregnancy: Pregnancy Category C. Animal reproduction studies have not been conducted with potassium chloride. It is also not known whether potassium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Potassium chloride should be given to a pregnant woman only if clearly needed.
🧒 Pediatric Use ▾
Pediatric Use: These products should not be used in pediatric patients at this time. Do not administer unless solution is clear and seal is intact.
🆘 Overdosage ▾
OVERDOSAGE In the event of hyperkalemia, discontinue the infusion immediately and institute corrective therapy to reduce serum potassium levels as necessary. The use of potassium containing foods or medications must also be eliminated. Treatment of mild to severe hyperkalemia with signs and symptoms of potassium intoxication includes the following: Dextrose Injection, USP, 10% or 25%, containing 10 units of crystalline insulin per 20 grams of dextrose administered intravenously, 300 to 500 mL per hour.
Absorption and exchange of potassium using sodium or ammonium cycle cation exchange resin, orally and as retention enema. Hemodialysis and peritoneal dialysis. In cases of digitalization, too rapid a lowering of plasma potassium concentration can cause digitalis toxicity.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Potassium is the major cation of body cells (160 mEq/liter of intracellular water) and is concerned with the maintenance of body fluid composition and electrolyte balance. Potassium participates in carbohydrate utilization, protein synthesis, and is critical in the regulation of nerve conduction and muscle contraction, particularly in the heart. Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base of the body are reflected by changes in the chloride concentration.
Normally about 80 to 90% of the potassium intake is excreted in the urine, the remainder in the stools and to a small extent, in the perspiration. The kidney does not conserve potassium well so that during fasting, or in patients on a potassium-free diet, potassium loss from the body continues resulting in potassium depletion. A deficiency of either potassium or chloride will lead to a deficit of the other.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Potassium Chloride Injection in flexible plastic containers is available as follows: NDC No. Potassium per container 0409–7074–26 10 mEq/100 mL 0990-7074-26 10 mEq/100 mL 0409–7075–14 10 mEq/50 mL 0990-7075-14 10 mEq/50 mL 0409–7075–26 20 mEq/100 mL 0990-7075-26 20 mEq/100 mL 0409–7077–14 20 mEq/50 mL 0990-7077-14 20 mEq/50 mL 0409–7077–26 40 mEq/100 mL 0990-7077-26 40 mEq/100 mL ICU Medical is transitioning NDC codes from "0409" to a "0990" labeler code. Both NDC codes are expected to be in the market for a period of time.
Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Revised: June, 2018 EN-4654 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA
📋 Description ▾
DESCRIPTION This Potassium Chloride Injection is a sterile, nonpyrogenic, highly concentrated, ready-to-use solution of Potassium Chloride, USP in Water for Injection, USP for electrolyte replenishment in a single dose container for intravenous administration. It contains no antimicrobial agents. Potassium Chloride Injection mEq Potassium/ Container Composition (g/L) Potassium Chloride, USP (KCl) Osmolarity* (mOsmol/L) (calc) pH Ionic Concentration (mEq/L) Potassium Chloride 10 mEq/100 mL 7.45 200 5.8 (4.0 to 8.0) 100 100 10 mEq/50 mL 20 mEq/100 mL 14.9 400 5.8 (4.0 to 8.0) 200 200 20 mEq/50 mL 40 mEq/100 mL 29.8 799 5.8 (4.0 to 8.0) 400 400 *Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L.
Administration of substantially hypertonic solutions (≥600 mOsmol/L) may cause vein damage. This flexible plastic container is fabricated from a specially formulated polyvinylchloride. Exposure to temperatures above 25°C (77°F) during transport and storage will lead to minor losses in moisture content.
Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly.
Solutions in contact with the plastic container may leach out certain of its chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials.
⚠️ Precautions ▾
PRECAUTIONS Laboratory Tests Serum potassium levels are not necessarily indicative of tissue potassium levels. Solutions containing potassium should be used with caution in the presence of cardiac or renal disease. Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
Significant deviations from normal concentrations may require the use of additional electrolyte supplements, or the use of electrolyte-free dextrose solutions to which individualized electrolyte supplements may be added. Pregnancy: Pregnancy Category C. Animal reproduction studies have not been conducted with potassium chloride.
It is also not known whether potassium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Potassium chloride should be given to a pregnant woman only if clearly needed. Pediatric Use: These products should not be used in pediatric patients at this time.
Do not administer unless solution is clear and seal is intact.
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL - 100 mL Bag Label For Use Only With A Calibrated Infusion Device Highly Concentrated 100 mEq/L 100 mL NDC 0990-7074-26 POTASSIUM CHLORIDE Inj. 10 mEq EACH 100 mL CONTAINS POTASSIUM CHLORIDE 745 mg IN WATER FOR INJECTION. ELECTROLYTES PER 1000 mL: POTASSIUM 100 mEq; CHLORIDE 100 mEq.
200 mOsmol/LITER (CALC.) pH 5.8 (4.0 to 8.0) DO NOT ADD SUPPLEMENTARY MEDICATION. WHENEVER POSSIBLE USE CENTRAL ROUTE. SINGLE-DOSE CONTAINER.
FOR I.V. USE. USUAL DOSAGE: SEE INSERT.
STERILE, NONPYROGENIC. USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES CONNECTIONS.
Rx ONLY 3 V CONTAINS DEHP ICU Medical, Inc., Lake Forest, Illinois, 60045, USA icumedical IM-4339 PRINCIPAL DISPLAY PANEL - 100 mL Bag Label
PRINCIPAL DISPLAY PANEL - 100 mL Bag Pouch Label TO OPEN – TEAR AT NOTCH NDC 0990-7074-26 For use only with a calibrated infusion device. HIGHLY CONCENTRATED 100 mEq/L POTASSIUM CHLORIDE Inj. 10 mEq Total in 100 mL Each 100 mL contains potassium chloride 745 mg in water for injection.
Electrolytes per 1000 mL: potassium 100 mEq; chloride 100 mEq. 200 mOsmol/liter (CALC.) pH 5.8 (4.0 to 8.0) DO NOT ADD SUPPLEMENTARY MEDICATION. WHENEVER POSSIBLE USE CENTRAL ROUTE.
Single-dose container. For I.V. use. Usual dosage: See insert.
Sterile, nonpyrogenic. Use only if solution is clear. After removing the overwrap, check for minute leaks by squeezing container firmly.
If leaks are found, discard unit as sterility may be impaired. Must not be used in series connections. The overwrap is a moisture barrier.
Do not remove unit from overwrap until ready for use. Use unit promptly when pouch is opened. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing.
See insert. Rx only 7 OTHER F WR-0529 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA icumedical PRINCIPAL DISPLAY PANEL - 100 mL Bag Pouch Label
PRINCIPAL DISPLAY PANEL - 50 mL Bag Label - IM-4340 For Use Only With A Calibrated Infusion Device Highly Concentrated 200 mEq/L 50 mL NDC 0990-7075-14 POTASSIUM CHLORIDE Inj. 10 mEq EACH 100 mL CONTAINS POTASSIUM CHLORIDE 1490 mg IN WATER FOR INJECTION. ELECTROLYTES PER 1000 mL: POTASSIUM 200 mEq; CHLORIDE 200 mEq.
400 mOsmol/LITER (CALC.) pH 5.8 (4.0 to 8.0) DO NOT ADD SUPPLEMENTARY MEDICATION. WHENEVER POSSIBLE USE CENTRAL ROUTE. SINGLE-DOSE CONTAINER.
USUAL DOSAGE: SEE INSERT. FOR I.V. USE.
STERILE, NONPYROGENIC. USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES CONNECTIONS.
Rx ONLY 3 V CONTAINS DEHP icumedical IM-4340 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA PRINCIPAL DISPLAY PANEL - 50 mL Bag Label - IM-4340
PRINCIPAL DISPLAY PANEL - 50 mL Bag Pouch Label - WR-0530 TO OPEN – TEAR AT NOTCH NDC 0990-7075-14 For use only with a calibrated infusion device. HIGHLY CONCENTRATED 200 mEq/L POTASSIUM CHLORIDE Inj. 10 mEq Total in 50 mL Each 100 mL contains potassium chloride 1490 mg in water for injection.
Electrolytes per 1000 mL: potassium 200 mEq; chloride 200 mEq. 400 mOsmol/liter (CALC.) pH 5.8 (4.0 to 8.0) DO NOT ADD SUPPLEMENTARY MEDICATION. WHENEVER POSSIBLE USE CENTRAL ROUTE.
Single-dose container. For I.V. use. Usual dosage: See insert.
Sterile, nonpyrogenic. Use only if solution is clear. After removing the overwrap, check for minute leaks by squeezing container firmly.
If leaks are found, discard unit as sterility may be impaired. Must not be used in series connections. The overwrap is a moisture barrier.
Do not remove unit from overwrap until ready for use. Use unit promptly when pouch is opened. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing.
See insert. Rx only 7 OTHER F WR-0530 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA icumedical PRINCIPAL DISPLAY PANEL - 50 mL Bag Pouch Label - WR-0530
PRINCIPAL DISPLAY PANEL - 50 mL Bag Label - IM-4342 For Use Only With A Calibrated Infusion Device Highly Concentrated 400 mEq/L 50 mL NDC 0990-7077-14 POTASS… [Excerpted — this section continues on DailyMed.]
Medicaid utilization & spend
Medicaid utilization by pack size
Medicare Part D spend CMS · PART D · 2026 (Q1)
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | ✓ Available |
| Medicaid utilization (CMS SDUD) | ✓ Available |